(NASDAQ: SCPH) Scpharmaceuticals's forecast annual revenue growth rate of 74.41% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.42%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Scpharmaceuticals's revenue in 2025 is $36,332,000.On average, 3 Wall Street analysts forecast SCPH's revenue for 2025 to be $3,842,697,549, with the lowest SCPH revenue forecast at $3,712,965,022, and the highest SCPH revenue forecast at $4,022,714,000. On average, 3 Wall Street analysts forecast SCPH's revenue for 2026 to be $6,854,503,520, with the lowest SCPH revenue forecast at $5,685,100,561, and the highest SCPH revenue forecast at $7,682,880,901.
In 2027, SCPH is forecast to generate $9,639,428,423 in revenue, with the lowest revenue forecast at $8,166,109,420 and the highest revenue forecast at $11,112,747,425.